HELPING THE OTHERS REALIZE THE ADVANTAGES OF ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Segment C, members will receive ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Members will acquire treatment till disease progression or perhaps the contributors are unable to tolerate the study drugs.Ubiquitin-associated proteins that control the stability of essential Tremendous enhancer-mediat